Collegium Pharmaceutical Receives a Buy from Piper Jaffray

By Jason Carr

Piper Jaffray analyst David Amsellem reiterated a Buy rating on Collegium Pharmaceutical (NASDAQ: COLL) on December 4 and set a price target of $24. The company’s shares closed yesterday at $17.21.

According to, Amsellem is a 2-star analyst with an average return of 0.1% and a 48.4% success rate. Amsellem covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, ACADIA Pharmaceuticals Inc, and Amphastar Pharmaceuticals.

Currently, the analyst consensus on Collegium Pharmaceutical is Strong Buy and the average price target is $24.20, representing a 40.6% upside.

In a report issued on December 5, Needham also maintained a Buy rating on the stock with a $28 price target.

Based on Collegium Pharmaceutical’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $11.95 million and GAAP net loss of $13.26 million. In comparison, last year the company earned revenue of $408K and had a GAAP net loss of $26.44 million.

Based on the recent corporate insider activity of 25 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of COLL in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company, which engages in the development and commercialization of next-generation abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. Its products includes Xtampza ER, and ONSOLIS.